Abstract Search

ea0077oc1.2 | Reproductive and Neuroendocrinology | SFEBES2021

Hyper-phosphorylation of β-catenin at Serine552 correlates with invasion and predicts recurrence of Non-Functioning Pituitary Tumours (NFPTs)

Rai Ashutosh , Yelamanchi Soujanya D. , Radotra Bishan D , Gupta Sunil K , Chhabra Rajesh , Pandey Akhilesh , Korbonits Marta , Gaston-Massuet Carles , Dutta Pinaki

Background: No predictive biomarkers for NFPT recurrence have been identified, apart from Ki67. We employed high-throughput mass spectrometry-based analyses to examine the phosphorylation pattern of different subsets of NFPTs. Methods: Based on histopathological, radiological and surgical features, NFPTs were sub-grouped into three groups: non-invasive (n = 15), invasive (n = 10) and recurrent (n = 5) subtypes. Invasiveness was...

0 shares

ea0086op3.2 | Reproductive and Neuroendocrinology | SFEBES2022

Identification of differentially activated pathways in recurrent non-functioning pituitary tumours using quantitative proteomics and bioinformatics analysis

Rai Ashutosh , Yelamanchi Soujanya D , Barry Sayka , Radotra Bishan D , Gupta Sunil K , Chhabra Rajesh , Pandey Akhilesh , Korbonits Marta , Dutta Pinaki

Background: No predictive biomarkers have been identified for clinically nonfunctioning pituitary tumour (NFPT) recurrence, with Ki67 being controversial. We employed quantitative mass spectrometry-based analyses to examine the differential expression of proteins in NFPTs.Methods: NFPTs were sub-grouped: non-invasive/non-recurrent group (NI/NR-G, n=5), invasive group (I-G, n=10) and recurrent group (R-G, n=5). Invasiveness was ...

0 shares

ea0025p242 | Pituitary | SFEBES2011

Pitfalls in transphenoidal surgery: a 10 years experience

Mukherjee Kanchan , Khosla Virender , Mathuriya Suresh , Bhansali Anil , Dutta Pinaki , Khandelwal Nilanjan , Singh Paramjeet , Vasishta Rakesh , Radotra Bhisham , Pathak Ashis , Gupta Sunil , Tewari Manoj , Chhabra Rajesh

Three hundred and thirty six cases of pituitary adenomas were operated by the transpenoidal route in the last 10 years by a single surgeon. Majority of these were giant non functioning adenomas. Prolactinomas were excluded unless a part of dual adenoma.In nearly 80% of tumours, total or near total removal was achieved. Long term outcome with follow up of more than 5 years revealed recurrence requiring resurgery in only 4 out of 102 patients. Endocrine re...

0 shares

ea0099p471 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Mandodari Rajurkar Dr , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis aimed to assess efficacy and safety of triple-drug FDC versus (vs) two-drug combination in T2DM Indian patients with HbA1c 9%-11%.<p class...

0 shares

ea0099ep337 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Rajurkar Mandodari , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis assessed efficacy and safety of triple-drug FDC vs (vs) two-drug combination in T2DM Indian patients aged <45 years and 45-65 years.<p...

0 shares

Endocrine Abstracts

Hyper-phosphorylation of β-catenin at Serine552 correlates with invasion and predicts recurrence of Non-Functioning Pituitary Tumours (NFPTs)

Identification of differentially activated pathways in recurrent non-functioning pituitary tumours using quantitative proteomics and bioinformatics analysis

Pitfalls in transphenoidal surgery: a 10 years experience

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

BiosciAbstracts